Application
Anti-KLHDC2 Prestige Antibodies® Powered by Atlas Antibodies is developed and validated by the Human Protein Atlas (HPA) project . Each antibody is tested by immunohistochemistry against hundreds of normal and disease tissues. These images can be viewed on the Human Protein Atlas (HPA) site by clicking on the Image Gallery link. The antibodies are also tested using immunofluorescence and western blotting. To view these protocols and other useful information about Prestige Antibodies and the HPA, visit sigma.com/prestige.
Biochem/physiol Actions
KLHDC2 (kelch domain containing 2) encodes a kelch repeat protein that is involved in the interaction and inhibition of transcription factor LZIP.
Features and Benefits
Prestige Antibodies® are highly characterized and extensively validated antibodies with the added benefit of all available characterization data for each target being accessible via the Human Protein Atlas portal linked just below the product name at the top of this page. The uniqueness and low cross-reactivity of the Prestige Antibodies® to other proteins are due to a thorough selection of antigen regions, affinity purification, and stringent selection. Prestige antigen controls are available for every corresponding Prestige Antibody and can be found in the linkage section.Every Prestige Antibody is tested in the following ways: IHC tissue array of 44 normal human tissues and 20 of the most common cancer type tissues. Protein array of 364 human recombinant protein fragments.
General description
The gene KLHDC2 is localized to chromosome 14q21.3 along with KLHDC1 and is predominantly found in the nucleus. The gene is highly expressed in skeletal muscle.
Immunogen
kelch domain containing 2 recombinant protein epitope signature tag (PrEST)
Legal Information
Prestige Antibodies is a registered trademark of Sigma-Aldrich Co. LLC
Linkage
Corresponding Antigen APREST70381.
Physical form
Solution in phosphate buffered saline, pH 7.2, containing 40% glycerol and 0.02% sodium azide.
This product has met the following criteria to qualify for the following awards: